Association of serum procalcitonin and C-reactive protein levels with CURB-65 criteria among patients with community-acquired pneumonia
- PMID: 29942144
- PMCID: PMC6005316
- DOI: 10.2147/IJGM.S165190
Association of serum procalcitonin and C-reactive protein levels with CURB-65 criteria among patients with community-acquired pneumonia
Abstract
Background: The concentration of diagnostic markers such as inflammatory biomarkers including procalcitonin (PCT) and C-reactive protein (CRP) increases in bacterial infections. The aim of this study was to compare serum PCT and CRP levels with CURB-65 ranking, in the patients with community-acquired pneumonia (CAP).
Patients and methods: In a cross-sectional study, 93 hospitalized patients with a definite diagnosis of CAP, considering inclusion and exclusion criteria, were enrolled. Serum PCT and CRP levels and their relations with CURB-65 criteria were assessed.
Results: The mean serum levels of PCT and CRP were 3.64±12.32 ng/mL and 75.01±51.93 mg/L, respectively. There was a statistically significant association between CURB-65 criteria and serum levels of PCT (P=0.0001) and CRP (P=0.007), which means that the concentration of these two inflammatory biomarkers increased with an increase in the score of CURB-65 criteria. Moreover, there was a statistically significant association between the serum level of PCT and the outcomes of the disease (P<0.001).
Conclusion: According to the results, the serum level of PCT or CRP is a strong prognostic factor for evaluating severity of CAP and is a suitable factor for the CURB-65 criteria in the decision making of whether a patient with CAP in the ICU should be admitted.
Keywords: C-reactive protein; CURB-65; community-acquired pneumonia; procalcitonin.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures



References
-
- Mandell LA, Wunderink RG. Pneumonia. In: Fauci A, Braunwald E, Kaser D, editors. Harrison’s Internal Medicine. 18th ed. New York: Mac Graw Hill; 2011. pp. 2130–2141.
-
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America; American Thoracic Society Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72. - PMC - PubMed
-
- Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis. 2011;52(Suppl 4):S346–S350. - PubMed
-
- Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006;32(3):469–472. - PubMed
-
- Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest. 2005;128(4):2223–2229. - PubMed
LinkOut - more resources
Full Text Sources